Wednesday, November 13, 2013, 1:00 p.m. - 1:55 p.m, Room 405
While there are still only a few early-stage bio-investors in China, the number of funding sources is starting to increase. Who is funding this innovation and what are their ultimate goals? Among them are international investment funds that have established China-based funds; corporations investing through their own venture arms, or as limited partners in funds; domestic VC firms; and government implemented programs, such as the successful Torch program from the Ministry of Science and Technology. All these funding resources are kick-starting Chinese biotech today. Where will this diversity of investments take China’s biotech industry in the coming years? Hear investors assess the current state of early-stage VC funding in China and the long-term outlook for biotech.
• Lianyong (Leon) Chen, Founder & Managing Partner, Frontline BioVentures
• Jonathan Wang, PhD, Senior Managing Director, OrbiMed Healthcare Fund Management
• Jimmy Zhang, PhD, Managing Director, MSD Early Investments, Greater China, Merck & Co.
• Yi Shi, PhD, Managing Director, Lilly Asia Ventures